

FOIA MARKER

**This is not a textual record. This is used as an
administrative marker by the William J. Clinton
Presidential Library Staff.**

Collection/Record Group: Clinton Presidential Records

Subgroup/Office of Origin: National AIDS Policy Office

Series/Staff Member:

Subseries:

OA/ID Number: 21072

FolderID:

Folder Title:

Colmar Enterprises, Inc.

Stack:

S

Row:

67

Section:

1

Shelf:

1

Position:

3

THE WHITE HOUSE
WASHINGTON

June 12, 2000

Margie M. Collins, RN
President
Colmar Enterprises, Inc.
2104 Miller Ferry Way
Huntsville, AL 35801

Dear Ms. Collins:

Thank you for your letter of May 2nd, 2000, in which you detailed your organization's involvement in the development of a single use syringe.

A non-reusable syringe would indeed address the significant issue of HIV transmission through the repeated use of syringes, both by injection drug users and medical professionals. As the Office of National AIDS Policy is primarily policy-oriented in our activities, the National Institutes of Health and Center for Disease Control may be better able to address the project you have presented. The National Institute on Drug Abuse (NIDA), in particular, is involved in researching the impact of injection-use on HIV infection, and can be reached through the web site of the National Institutes of Health at <http://www.nih.gov>.

Thank you again for your letter, and I wish you all the best with your work!

Sincerely,

Sandra L. Thurman
Director
Office of National AIDS Policy

sent 6/14/00

COLMAR ENTERPRISES, INC.

2104 Miller Ferry Way

Huntsville, AL 35801

Phone: (256) 881-9818

Fax: (256) 881-6677

E-mail: colmar@hiwaay.net

May 2, 2000

Office of National AIDS Policy

736 Jackson Place

Washington, DC 20503


Dear Ms. Thurman,

In a recent speech, President Clinton indicated that the United States would be aggressively addressing the current epidemic of HIV/AIDS transmission in developing countries such as Africa. In addition to the sexual transmission of HIV, reuse of hypodermic syringes is another significant source for transmission of bloodborne pathogens. In these developing countries, conventional syringes are routinely reused multiple times with the resulting infection of many individuals. This syringe reuse has the potential for millions of additional incidences of AIDS in developing nations.

My company, Colmar Enterprises, Inc. (CEI), is involved with the development of safety syringe devices to prevent accidental percutaneous needlestick injuries among healthcare providers in the United States. During R&D on safety syringe designs for the U.S. market, CEI devised a single-use, non-reusable syringe that could be the syringe of choice when providing medical supplies to developing countries. This single-use system positively prevents the reuse of a contaminated syringe. This syringe device could prove significant in reducing the transmission of HIV/AIDS in developing countries.

I am seeking a contact within your organization to arrange an appointment to discuss this important issue. Your assistance will be appreciated.

Sincerely,



Margie M. Collins, RN
President

policy v. res.
NIH → website
AID → injection
drug use